Which drug works best for cirrhosis patients with bleeding and kidney trouble?
NCT ID NCT07252401
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two drugs, terlipressin and somatostatin, in 64 adults with liver cirrhosis who have acute gastrointestinal bleeding and acute kidney injury. Both drugs are given intravenously for up to 5 days. The main goal is to see which drug better reverses kidney injury. This is a randomized controlled trial, meaning patients are assigned to one drug or the other by chance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
terlipressin (also known as Terlivaz) and somatostatin (also known as Stilamin)
What this could lead to
If terlipressin proves better, it could become the preferred treatment for cirrhosis patients with both bleeding and kidney injury, potentially improving outcomes.
What could go wrong
This is a small, early-stage trial with only 64 participants, so results may not apply to all patients. The treatment is short-term (5 days) and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)
Shenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••